Literature DB >> 24300305

Coeliac disease screening in first-degree relatives on the basis of biopsy and genetic risk.

Luis Vaquero1, Alberto Caminero, Alejandro Nuñez, Mercedes Hernando, Cristina Iglesias, Javier Casqueiro, Santiago Vivas.   

Abstract

BACKGROUND: Serological markers of coeliac disease (CD) lack diagnostic value to identify mild histopathological lesions mainly in adults at risk of CD. AIMS: The aim of this study was to evaluate the usefulness of human leukocyte antigen (HLA)-DQ2/8 genotyping, followed by duodenal biopsy for the detection of CD in adult first-degree relatives (FDRs) of patients with CD.
MATERIALS AND METHODS: Ninety-two adult DQ2/8 positive FDRs were consecutively included. A duodenal biopsy was offered irrespective of the serology result or associated symptoms. The clinical features, associated autoimmune diseases and biochemical parameters were recorded.
RESULTS: Sixty-seven FDRs (mean age 34 years) underwent a duodenal biopsy. Histopathological alterations were found in 32 (48%) and showed the following stages: 12 Marsh I (18%), one Marsh II (1.5%), four Marsh IIIA (6%), five Marsh IIIB (7.5%) and 10 Marsh IIIC (15%). Positive serological markers were present in 17/67 (25%), with only one showing Marsh I and the remainder presenting some degree of duodenal atrophy (Marsh III). In addition, 33/67 (54%) had gastrointestinal symptoms, with dyspepsia being the most prevalent. The distribution of symptoms, anaemia and autoimmune disease was independent of the duodenal histopathological stage. Serology-based screening would diagnose 50% of the cases showing any degree of CD spectrum and miss 6% of the cases with mucosal atrophy.
CONCLUSION: Adult FDRs of patients with CD can benefit from a screening strategy on the basis of HLA-DQ genotyping, followed by a duodenal biopsy. Gastrointestinal symptoms and lymphocytic enteritis are common findings that may benefit from a gluten-free diet.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24300305     DOI: 10.1097/MEG.0000000000000020

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

Review 1.  Age-related differences in celiac disease: Specific characteristics of adult presentation.

Authors:  Santiago Vivas; Luis Vaquero; Laura Rodríguez-Martín; Alberto Caminero
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

Review 2.  Risk of Celiac Disease in the First- and Second-Degree Relatives of Patients With Celiac Disease: A Systematic Review and Meta-Analysis.

Authors:  Prashant Singh; Shubhangi Arora; Suman Lal; Tor A Strand; Govind K Makharia
Journal:  Am J Gastroenterol       Date:  2015-09-29       Impact factor: 10.864

3.  Appropriate clinical use of human leukocyte antigen typing for coeliac disease: an Australasian perspective.

Authors:  J A Tye-Din; D J S Cameron; A J Daveson; A S Day; P Dellsperger; C Hogan; E D Newnham; S J Shepherd; R H Steele; L Wienholt; M D Varney
Journal:  Intern Med J       Date:  2015-04       Impact factor: 2.048

4.  The frequency of HLA-DQ2/DQ8 haplotypes and celiac disease among the first-degree relatives of patients with celiac disease.

Authors:  Masoume Mansouri; Masoud Dadfar; Mohammad Rostami-Nejad; Golnaz Ekhlasi; Amirhossein Shahbazkhani; Bijan Shahbazkhani
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2021

5.  Frequency of celiac disease and distribution of HLA-DQ2/DQ8 haplotypes among siblings of children with celiac disease.

Authors:  Yasin Sahin; Serdar Mermer
Journal:  World J Clin Pediatr       Date:  2022-07-09

Review 6.  Descriptive Study of the Different Tools Used to Evaluate the Adherence to a Gluten-Free Diet in Celiac Disease Patients.

Authors:  Luis Rodrigo; Isabel Pérez-Martinez; Eugenia Lauret-Braña; Adolfo Suárez-González
Journal:  Nutrients       Date:  2018-11-16       Impact factor: 5.717

7.  Celiac Disease: A Common Unrecognized Health Problem with a Very Delayed Diagnosis.

Authors:  Luis Rodrigo
Journal:  Medicina (Kaunas)       Date:  2019-12-26       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.